Team

Who We Are

We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47.

Our Technology

DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells.

                      Lab Team in Edmonton, Alberta: Iain Wilson, Gabrielle Siegers (Head of R&D), Baomin Tian and Wah Wong

Experienced Leadership

Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills.
The group is committed to developing novel medicines through DOS47 platform technology.

Praveen Varshney

Mr. Praveen Varshney has been a principal of Varshney Capital Corp., a Vancouver based family office, since 1991.  He's also a Founding Director of Pyfera Growth Capital & a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus.  Mr. Varshney obtained his UBC Sauder BComm in 1987 and is a FCPA, FCA.  He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director & Charter Member of TiE Vancouver since 2000.
↪

Management Team

Jacek Antas

Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting. Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various companies throughout his career.
↪

Jacek Antas
Chief Executive Officer

Dr. Srikanth Sola

Dr. Srikanth Sola is cardiologist with a strong science and research background, expertise in cardiac oncology, drug development and physician leadership. After graduating from Stanford University, he completed various aspects of his medical training at the University of Louisville, Harvard Medical School, Duke University, and Emory University. As a member of the Department of Cardiology’s Imaging Section, he was an active member of the Cleveland Clinic’s cardio-oncology program and the cardiac imaging core lab.
↪

Dr. Srikanth Sola
Chief Strategy Officer

Praveen Varshney

Mr. Praveen Varshney has been a principal of Varshney Capital Corp., a Vancouver based family office, since 1991.  He's also a Founding Director of Pyfera Growth Capital & a Founding Director of Humanitas Smart Planet Fund, both with a social impact focus.  Mr. Varshney obtained his UBC Sauder BComm in 1987 and is a FCPA, FCA.  He has been a member of the Vancouver Chapter of EO since 1996 and a founding Director & Charter Member of TiE Vancouver since 2000.
↪

Praveen Varshney
Chief Financial Officer

Dr. Thomas Mehrling

Dr. Dr. med Thomas Mehrling is a PhD pharmacologist and a MD in Internal Medicine-Hemato-Oncology from the University of Frankfurt. In more than 20 years in the industry, he has been building oncology businesses from scratch and, being at the helm of development and commercialization of oncology products across 17 European countries, taking them to success. His experience ranges from designing focused and streamlined development plans for oncology small molecules and biologics and taking them to approval, as well as taking the commercial lead. He has gained experience in market introductions beyond Europe through collaborations with established Pharma companies like Cephalon, Teva, BioCryst and Skypharma in the US, Takeda and Astellas in Japan and several companies in Asia.

Dr. Thomas Mehrling
Chief Medical Officer

Christof Bohler

Dr. Christof Boehler is a commercially oriented scientist with a proven track record in building and leading teams that successfully commercialize products and services in the life science industry. His core competencies are in technology transfer, business development and corporate governance with a focus on technology scouting, preclinical and clinical R&D, licensing, sales, capital raising and M&A. Mr. Boehler is also a strategic advisor to Takeda.
↪

Christof Boehler
Chief Business Development

Board of Directors

Jacek Antas

Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting. Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various companies throughout his career.
↪

Jacek Antas
Chairman of the Board

Malgorzata Laube

Malgorzata Laube has over 19 years of experience in nuclear medicine. In her last role with Alberta Health Services, she was the Department Supervisor, Nuclear Medicine at Royal Alexandra Hospital. Ms. Laube obtained a MSc degree in Environmental Engineering from the Warsaw University of Technology and is based in Edmonton, Alberta, Canada.
↪

Malgorzata Laube
Director

Jerzy Leszczynski

Jerzy Leszczynski is a shareholder of the Company, has spent more than 35 years developing businesses and has served in the capacity of board member of various real estate development companies. Mr. Leszczynski obtained his Master of Science in Chemistry from the Warsaw Institute of Technology.
↪

Jerzy Leszczynski
Director

Janusz Grabski

Janusz Grabski is a lawyer specialized in corporate and real estate law with over twenty years of experience.
↪

Janusz Grabski
Director, Chair of Audit Committee

Scientific Team

Kim Gaspar, Ph.D

Kim is the Director of Quality Assurance at Helix BioPharma Corp. An experienced quality assurance professional with expertise in Canadian, US, and EU regulations, she has been involved in all aspects of Phase I/II biopharmaceutical product development over the years, including regulatory submissions, QC laboratory compliance, tech transfer and third-party oversight of CMC activities, clinical QA, and bioanalytical data analysis...
↪

Kim Gaspar, PhD
Director Quality Assurance

Gabrielle M. Siegers

Gabrielle is the Head of Research & Development for Helix BioPharma Corp. She carried out doctoral research at the Max Planck Institute for Immunobiology (Freiburg, Germany) and postdoctoral research at the Princess Margaret Hospital (Toronto, ON) and Robarts Research Institute (London, ON)...
↪

Gabrielle M. Siegers, PhD
Head of Research & Development

Iain Wilson

Iain Wilson earned his BSc. in Chemistry at the University of Alberta after which he worked in the toxicology lab at the Office of the Chief Medical Examiner in Edmonton. Iain then took a position synthesizing peptides at the Protein Engineering Network of Centers of Excellence at the University of Alberta...
↪

Iain Wilson BSc. in Chemistry
Research Technician

Brenda Lee

Brenda is the Clinical Operations Director at Helix Biopharma Corp. A clinical research operations professional with 25 years of experience managing clinical trials, ranging from early Phase I to late Phase IIIb/IV studies, she brings experience in clinical study protocol writing and development, trial start-up and vendor management, and a proven track record in planning and managing clinical trials to quality standards, timelines and budget...
↪

Brenda Lee, M.Sc.
Director Clinical Operations

Wah Y. Wong

Wah earned his PhD in Biochemistry from the University of Alberta and then completed a fellowship in Medical Microbiology and Immunology with the Protein Engineering Network of Centers of Excellence. He has extensive research experience in protein chemistry, bacterial pathogenesis, vaccine and immunoassay development, and molecular biology...
↪

Wah Y. Wong, PhD
Laboratory Director

Dr. Praveen Kumar

Praveen has experience working in the pharmaceutical industry for more than 25 years and has expertise in the development of drug products for small and macro-molecules using various dosage forms.
↪

Praveen Kumar, PhD
V.P. Drug Development 

Baomin Tian

Baomin Tian earned his PhD in Chemistry at New Mexico State University (USA) followed by a postdoctoral research fellowship at the Protein Engineering Network of Centers of Excellence at the University of Alberta...
↪

Baomin Tian, PhD
Senior Scientist